Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05307237 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)
A NA study, sponsored by Scripps Whittier Diabetes Institute.
- Completed
- Registry status
- NA
- Development phase
- 518
- Enrollment target
NCT05307237: Completed NA study, sponsored by Scripps Whittier Diabetes Institute.
NCT05307237 is a NA study that has completed, run by Scripps Whittier Diabetes Institute. The registered enrollment target is 518 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05307237, a NA study, has completed, sponsored by Scripps Whittier Diabetes Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 518 participants
- Enrollment target
Study Summary
Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an underserved and understudied, yet high-risk population. A digital dashboard will facilitate real-time, remote monitoring of a large volume of patients simultaneously; automatically identify and prioritize patients for intervention; and will detect any and all potentially dangerous hypoglycemic episodes in a hospital environment. The study will focus on clinical metrics of glucose control and infection that are in-line with patient priorities and US hospital quality initiatives.
Primary Outcome
Participants will have their percent time in range calculated following a minimum CGM data collection period of 12 hours and expressed as a percentage where: Percent Time in Range= 100 (Number readings in range (70-200mg/dL)/Total number of readings from CGM). Number of readings will be used in calculation, which scale directly with time.
Interventions
- DEVICE Dexcom G6 Continous Glucose Monitoring Management
- DEVICE Usual Care - Blinded Continuous Glucose Monitoring Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2025-12-17 |
| Phase | NA |
What the finished NCT05307237 record still lists
NCT05307237 is an interventional study that assigns participants to a tested intervention. The registered 518 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexcom G6 Continous Glucose Monitoring Management is the first listed.
NCT05307237 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05307237 about?
NCT05307237 is a clinical study titled "Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)". Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an unde...
What is the current status of trial NCT05307237?
This trial is currently completed. It is a NA study. The enrollment target is 518 participants. The study started on 2022-04-19. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT05307237?
The interventions under investigation include: Dexcom G6 Continous Glucose Monitoring Management (DEVICE), Usual Care - Blinded Continuous Glucose Monitoring Management (DEVICE).
Who is sponsoring clinical trial NCT05307237?
This trial is sponsored by Scripps Whittier Diabetes Institute, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05307237's enrollment target sits among peer trials
518 191st of 2000 higher than 1,810 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT07112196 · 518 participants · Phase 2
Visugromab in Cachexia International Trial
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI